Should I buy or sell Prime Medicine stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prime Medicine in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRME shares. View PRME analyst ratings or view top-rated stocks .

What is Prime Medicine's stock price target for 2024?

9 analysts have issued 12-month price objectives for Prime Medicine's shares. Their PRME share price targets range from $9.00 to $26.00. On average, they expect the company's share price to reach $16.88 in the next twelve months. This suggests a possible upside of 242.3% from the stock's current price. View analysts price targets for PRME or view top-rated stocks among Wall Street analysts .

How have PRME shares performed in 2024?

Prime Medicine's stock was trading at $8.86 on January 1st, 2024. Since then, PRME shares have decreased by 44.4% and is now trading at $4.93. View the best growth stocks for 2024 here .

When is Prime Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PRME earnings forecast .

How were Prime Medicine's earnings last quarter?

Prime Medicine, Inc. (NYSE:PRME) posted its quarterly earnings results on Friday, March, 1st. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.08.

What ETFs hold Prime Medicine's stock?

ETFs with the largest weight of Prime Medicine (NYSE:PRME) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) , TrueShares Technology, AI & Deep Learning ETF (LRNZ) , ARK Genomic Revolution ETF (ARKG) and iShares Genomics Immunology and Healthcare ETF (IDNA) . ARK Innovation ETF (ARKK) .

When did Prime Medicine IPO?

Prime Medicine (PRME) raised $175 million in an initial public offering (IPO) on Thursday, October 20th 2022. The company issued 10,294,118 shares at a price of $16.00-$18.00 per share.

Who are Prime Medicine's major shareholders?

Prime Medicine's stock is owned by a number of institutional and retail investors. Top institutional shareholders include TrueMark Investments LLC (0.07%) and Green Alpha Advisors LLC (0.03%). Insiders that own company stock include 2019 Gp LLC Gv and Robert Nelsen. View institutional ownership trends .

How do I buy shares of Prime Medicine?

Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:PRME

Prime Medicine (PRME) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free PRME Stock Alerts

$4.93

-0.34 (-6.45%)

(As of 04/17/2024 ET)

Compare

Today's Range: $4.92
▼
$5.32
50-Day Range: $4.93
▼
$9.39
52-Week Range: $4.92
▼
$17.20

Volume: 652,428 shs
Average Volume: 666,971 shs
Market Capitalization: $591.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.88

Get Prime Medicine alerts:

Prime Medicine MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 242.3% Upside
$16.88 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.35
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$20 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.80) to ($1.65) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.04 out of 5 stars

Medical Sector

346th out of 913 stocks

Biological Products, Except Diagnostic Industry

47th out of 134 stocks

3.3

Analyst's Opinion

Consensus Rating
Prime Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Prime Medicine has only been the subject of 3 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for PRME.

0.0

Dividend Strength

Dividend Yield
Prime Medicine does not currently pay a dividend.
Dividend Growth
Prime Medicine does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRME.

3.0

News and Social Media Coverage

News Sentiment
Prime Medicine has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Prime Medicine this week, compared to 1 article on an average week.
Search Interest
4 people have searched for PRME on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
7 people have added Prime Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prime Medicine insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,000,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
24.29% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
70.37% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Prime Medicine are expected to grow in the coming year, from ($1.80) to ($1.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Prime Medicine is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prime Medicine is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Prime Medicine has a P/B Ratio of 3.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Market Moving Trends

Top 5 AI Stocks to Buy for 2024

5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

About Prime Medicine Stock (NYSE:PRME)

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

PRME Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRME Stock News Headlines

April 12, 2024 | americanbankingnews.com

Prime Medicine (NYSE:PRME) Shares Gap Down to $6.18

April 10, 2024 | uk.investing.com

TD Cowen initiates Prime Medicine stock with Buy on editing platform

April 18, 2024 | Timothy Sykes (Ad)

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

April 9, 2024 | americanbankingnews.com

Prime Medicine (NYSE:PRME) Now Covered by TD Cowen

April 8, 2024 | americanbankingnews.com

Analysts Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $16.88

March 27, 2024 | fool.com

2 Magnificent Growth Stocks With Room to Run

March 15, 2024 | cnet.com

13 Best Little-Known Perks You Can Get From Amazon Prime

March 14, 2024 | msn.com

Geron wins FDA AdCom backing for blood cancer drug

April 18, 2024 | Timothy Sykes (Ad)

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

March 14, 2024 | investorplace.com

Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging

March 12, 2024 | markets.businessinsider.com

Buy Rating Justified: Prime Medicine’s Promising Clinical Prospects and Innovative Gene Editing Technology Poised for Growth

March 12, 2024 | msn.com

Blinken to travel to Jamaica for CARICOM meeting on Haiti, US State Dept says

March 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Prime Medicine, Inc. on Anticipated IND Filing and Strong Gene Editing Pipeline

March 1, 2024 | investorplace.com

Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?

March 1, 2024 | benzinga.com

Recap: Prime Medicine Q4 Earnings

March 1, 2024 | msn.com

Prime Medicine GAAP EPS of -$2.18

March 1, 2024 | globenewswire.com

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

February 29, 2024 | benzinga.com

Thomas Cahill's Net Worth

February 28, 2024 | globenewswire.com

Prime Medicine to Participate in Upcoming Investor Conferences

February 27, 2024 | 247wallst.com

Stock Offerings Prompt Big Insider Buying

February 23, 2024 | finance.yahoo.com

PRME Mar 2024 12.500 call

February 20, 2024 | globenewswire.com

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

February 15, 2024 | finanznachrichten.de

Prime Medicine, Inc.: Prime Medicine Announces Pricing of Upsized Public Offering

February 15, 2024 | msn.com

Prime Medicine down 5%, prices $140M stock offering

February 15, 2024 | finance.yahoo.com

Prime Medicine Announces Pricing of Upsized Public Offering

February 14, 2024 | globenewswire.com

Prime Medicine Announces Pricing of Upsized Public Offering

February 14, 2024 | finance.yahoo.com

Prime Medicine Announces Proposed Public Offering of Common Stock

See More Headlines

Receive PRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/01/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NYSE:PRME
CUSIP: N/A
CIK: 1894562
Web: primemedicine.com
Phone: 617-564-0013
Fax: N/A
Employees: 234
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.88
High Stock Price Target: $26.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +220.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-198,130,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -87.30%
Return on Assets: -71.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.53
Quick Ratio: 2.53

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.37 per share
Price / Book: 3.85

Miscellaneous

Outstanding Shares: 119,940,000
Free Float: 90,806,000
Market Cap: $632.08 million
Optionable: Optionable
Beta: 1.80

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Keith Michael Gottesdiener Ph.D. (Age 70)
President, CEO, Secretary & Director
Comp: $924.04k
Dr. Ann L. Lee Ph.D. (Age 62)
Chief Technical Officer
Comp: $947.28k
Mr. Richard Brudnick (Age 66)
Chief Business Officer
Comp: $680.8k
Dr. Andrew Anzalone M.D. (Age 37)
Ph.D., Co-Founder & Head of Prime Editing Platform
Dr. David R. Liu Ph.D.
Co-Founder & Chair of Scientific Advisory Board
Dr. Allan Reine M.D. (Age 49)
Chief Financial Officer
Dr. Meredith Goldwasser (Age 52)
Senior VP and Head of Strategy & Corporate Operations
Ms. Carman Alenson CPA (Age 58)
M.B.A., Senior VP of Finance & Chief Accounting Officer
Dr. Jeremy S. Duffield M.D. (Age 56)
Ph.D., Chief Scientific Officer
Comp: $994.4k
Dr. Karen Brown J.D.
Ph.D., Senior Vice President of Intellectual Property & Legal Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRME Stock Analysis - Frequently Asked Questions

Should I buy or sell Prime Medicine stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prime Medicine in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRME shares.
View PRME analyst ratings or view top-rated stocks.
What is Prime Medicine's stock price target for 2024?: 9 analysts have issued 12-month price objectives for Prime Medicine's shares. Their PRME share price targets range from $9.00 to $26.00. On average, they expect the company's share price to reach $16.88 in the next twelve months. This suggests a possible upside of 242.3% from the stock's current price.
View analysts price targets for PRME or view top-rated stocks among Wall Street analysts.
How have PRME shares performed in 2024?: Prime Medicine's stock was trading at $8.86 on January 1st, 2024. Since then, PRME shares have decreased by 44.4% and is now trading at $4.93.
View the best growth stocks for 2024 here.
When is Prime Medicine's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PRME earnings forecast.
How were Prime Medicine's earnings last quarter?: Prime Medicine, Inc. (NYSE:PRME) posted its quarterly earnings results on Friday, March, 1st. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.08.

What ETFs hold Prime Medicine's stock?: ETFs with the largest weight of Prime Medicine (NYSE:PRME) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), TrueShares Technology, AI & Deep Learning ETF (LRNZ), ARK Genomic Revolution ETF (ARKG) and iShares Genomics Immunology and Healthcare ETF (IDNA).ARK Innovation ETF (ARKK).
When did Prime Medicine IPO?: Prime Medicine (PRME) raised $175 million in an initial public offering (IPO) on Thursday, October 20th 2022. The company issued 10,294,118 shares at a price of $16.00-$18.00 per share.
Who are Prime Medicine's major shareholders?: Prime Medicine's stock is owned by a number of institutional and retail investors. Top institutional shareholders include TrueMark Investments LLC (0.07%) and Green Alpha Advisors LLC (0.03%). Insiders that own company stock include 2019 Gp LLC Gv and Robert Nelsen.
View institutional ownership trends.
How do I buy shares of Prime Medicine?: Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:PRME) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Prime Medicine (PRME) Stock Price, News & Analysis

Prime Medicine MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Prime Medicine Stock (NYSE:PRME)

PRME Stock Price History

PRME Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PRME Stock Analysis - Frequently Asked Questions

Overall MarketRank^™